The agency's approval of alemtuzumab leaves neurologists wondering when unblinded studies are appropriate for pivotal multiple sclerosis trials.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Dolgin, E. FDA reversal sends mixed message to multiple sclerosis community. Nat Rev Drug Discov 14, 3–4 (2015). https://doi.org/10.1038/nrd4526
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4526